PDLIM2, also known as Mystique, contains an amino-terminal PDZ domain and a carboxy-terminal LIM domain. PDLIM2 was orginally found to be associated with cytoskeletal proteins in epithelial cells to promote cell attachment and migration. Subsequent studies have shown that PDLIM2 can also inhibit NF-κB activity by acting as a nuclear ubiquitin E3 ligase for p65. PDLIM2 is suppressed in cancer cell lines by DNA methylation. Expression of PDLIM2 can inhibit anchorage-independent growth and tumor formation.
[1] Torrado, M. et al. (2004) Invest Ophthalmol Vis Sci 45, 3955-63.
[2] Loughran, G. et al. (2005) Mol Biol Cell 16, 1811-22.
[3] Tanaka, T. et al. (2007) Nat Immunol 8, 584-91.
[4] Qu, Z. et al. (2010) Cancer Res 70, 1766-1772.
[5] Qu, Z. et al. (2010) J Biol Chem 285, 11786-92.